Bcr-Abl
Gli inibitori di Bcr-Abl sono terapie mirate che inibiscono la proteina di fusione Bcr-Abl, formata a seguito della traslocazione del cromosoma Philadelphia e responsabile della leucemia mieloide cronica (CML). Questa proteina influenza anche l'angiogenesi, contribuendo alla progressione tumorale. Gli inibitori di Bcr-Abl sono cruciali nel trattamento della CML e sono oggetto di ricerca per il loro potenziale nell'inibire l'angiogenesi in vari tipi di cancro. Presso CymitQuimica, offriamo inibitori di Bcr-Abl di alta qualità per supportare la tua ricerca in biologia del cancro, angiogenesi e terapie mirate.
Trovati 116 prodotti di "Bcr-Abl"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Formula:C24H27ClN6O4Colore e forma:SolidPeso molecolare:498.96BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formula:C22H20N4O3Colore e forma:SolidPeso molecolare:388.42TG-100435
CAS:TG-100435 is a novel multi-target oral protein tyrosine kinase inhibitor. The metabolic flux of TG100435 is entirely inhibited by methimazole and ketoconazole. In human liver microsomes or recombinant P450, the formation of TG100435 increases with the activity of cytochrome P450 reductase, suggesting that cytochrome P450 reductase may be involved.Formula:C26H25Cl2N5OPeso molecolare:494.42HG-7-85-01-NH2
CAS:HG-7-85-01-NH2, as the ligand for SNIPER(ABL)-033, effectively induces the reduction of BCR-ABL protein. This is achieved through SNIPER(ABL)-033, which connects HG-7-85-01 (an ABL inhibitor) to an LCL161 derivative (an IAP ligand) using a linker, demonstrating a DC50 value of 0.3 μM [1].Formula:C27H27F3N6OSColore e forma:SolidPeso molecolare:540.6c-ABL-IN-1
CAS:C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's diseaseFormula:C17H16Cl2FN3OSColore e forma:SolidPeso molecolare:400.29Asciminib hydrochloride
CAS:Asciminib hydrochloride is a STAMP inhibitor targeting the ABL myristoyl pocket, applied in Ph+ CML research for selective oncogenic signaling modulation.Formula:C20H19Cl2F2N5O3Purezza:99.91%Colore e forma:SolidPeso molecolare:486.3BGG463
CAS:BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Formula:C30H29F3N6O3Purezza:98.21% - >99.99%Colore e forma:SolidPeso molecolare:578.58GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formula:C28H24F3N7O2Purezza:97.05% - 99.7%Colore e forma:SolidPeso molecolare:547.53Degrasyn
CAS:Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.Formula:C19H18BrN3OPurezza:98.32% - 99.98%Colore e forma:SolidPeso molecolare:384.27Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formula:C14H11N3O3SPurezza:98% - 99.91%Colore e forma:Physical Description White Powder (Ntp 1992)Peso molecolare:301.32Rebastinib
CAS:<p>DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,</p>Formula:C30H28FN7O3Purezza:99.53% - 99.79%Colore e forma:SolidPeso molecolare:553.59Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormula:C29H27F3N6OPurezza:98% - 99.60%Colore e forma:SolidPeso molecolare:532.56NVP-BAW2881
CAS:NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor with activity to inhibit chronic and acute skin inflammation.Formula:C22H15F3N4O2Purezza:98.19% - 99.97%Colore e forma:SolidPeso molecolare:424.38AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formula:C19H23N7O2Purezza:99.83% - 99.98%Colore e forma:SolidPeso molecolare:381.43Multi-kinase inhibitor 1
CAS:Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Formula:C20H17F3N4O3Purezza:99.34%Colore e forma:SolidPeso molecolare:418.37Flumatinib
CAS:Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.Formula:C29H29F3N8OPurezza:99.39% - 99.95%Colore e forma:SolidPeso molecolare:562.59AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formula:C14H13BrN2OPurezza:98% - 99.37%Colore e forma:SolidPeso molecolare:305.17Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formula:C29H27F3N6O·2CH4O3SPurezza:97.66% - >99.99%Colore e forma:SolidPeso molecolare:724.77Dasatinib N-oxide
CAS:<p>Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.</p>Formula:C22H26ClN7O3SPurezza:98.54% - 99.94%Colore e forma:SolidPeso molecolare:504Olverembatinib
CAS:Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Formula:C29H27F3N6OPurezza:98.53% - >99.99%Colore e forma:SolidPeso molecolare:532.56
